Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-03-05 4:59 pm Unchanged | 13D | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 34.6% | 0 (Unchanged) | View |
| 2024-02-15 08:00 am Sale | 13G | HELIX ACQUISITION CORP SH HLXA | Merck Healthcare KGaA | 2,787,509 4.7% | -542,722 (-16.30%) | View |
| 2024-02-14 4:57 pm Sale | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | CITADEL ADVISORS LLC | 2,034,260 3.4% | -851,832 (-29.52%) | View |
| 2024-02-14 3:05 pm Purchase | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | Chen Bihua | 8,494,151 14.17% | 1,602,051 (+23.24%) | View |
| 2024-02-09 09:28 am Purchase | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | FMR LLC | 3,847,677 6.419% | 2,654,677 (+222.52%) | View |
| 2023-06-30 4:41 pm Unchanged | 13D | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 35.8% | 0 (Unchanged) | View |
| 2023-03-31 4:23 pm Purchase | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | Chen Bihua | 6,892,100 17.6% | 6,892,100 (New Position) | View |
| 2023-02-14 12:38 pm Purchase | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | PRICE T ROWE ASSOCIATES INC | 822,601 2.1% | 822,601 (New Position) | View |
| 2023-02-14 08:26 am Purchase | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | CITADEL ADVISORS LLC | 2,886,092 7.4% | 2,886,092 (New Position) | View |
| 2023-02-09 12:48 pm Purchase | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | FMR LLC | 1,193,000 3.23% | 1,193,000 (New Position) | View |
| 2023-02-09 10:09 am Unchanged | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 0 0% | 0 (Unchanged) | View |
| 2023-01-27 06:13 am Unchanged | 13G | HELIX ACQUISITION CORP SH HLXA | Merck Healthcare KGaA | 3,330,231 7.9% | 0 (Unchanged) | View |
| 2022-08-03 06:17 am Purchase | 13G | HELIX ACQUISITION CORP SH HLXA | Merck Healthcare KGaA | 3,330,231 8.3% | 3,330,231 (New Position) | View |
| 2022-04-18 4:49 pm Purchase | 13D | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 58.9% | 21,751,284 (New Position) | View |
| 2022-02-14 2:35 pm Sale | 13G | HELIX ACQUISITION CORP SH HLXA | PRICE T ROWE ASSOCIATES INC | 746,862 6.2% | -40,923 (-5.19%) | View |
| 2022-02-14 06:12 am Sale | 13G | HELIX ACQUISITION CORP SH HLXA | CITADEL ADVISORS LLC | 686,007 5.8% | -1,071 (-0.16%) | View |
| 2022-02-03 4:41 pm Sale | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | BlackRock Inc. BLK | 741,906 6.2% | -8,247 (-1.10%) | View |
| 2021-12-10 08:52 am Purchase | 13G | HELIX ACQUISITION CORP SH HLXA | FMR LLC | 1,193,000 10% | 1,193,000 (New Position) | View |
| 2021-11-15 4:34 pm Sale | 13G | HELIX ACQUISITION CORP SH HLXA | RA CAPITAL MANAGEMENT L.P. | 0 0% | -700,000 (Position Closed) | View |
| 2021-02-16 4:39 pm Purchase | 13G | HELIX ACQUISITION CORP SH HLXA | RA CAPITAL MANAGEMENT L.P. | 700,000 5.9% | 700,000 (New Position) | View |